Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: a systematic review and meta-analysis
BMC Cardiovascular Disorders · 2024
DOI: 10.1186/s12872-024-04029-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BMC Cardiovascular Disorders, 2024. Verfasst von Bijaya K Padhi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) are commonly prescribed for gastroprotection in patients undergoing percutaneous coronary intervention (PCI), who are at increased risk of gastrointestinal bleeding due to antiplatelet therapy. However, emerging evidence suggests that PPIs may adversely impact cardiovascular outcomes. This systematic review and meta-analysis sought to assess the relationship between using PPIs and cardiovascular outcomes in patients following PCI.
Methods
We searched various databases up to March 15, 2024, for observational studies and randomized controlled trials (RCTs) assessing the cardiovascular effects of PPIs in PCI patients. Data were extracted on study characteristics, patient demographics, PPI use, and cardiovascular outcomes. The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool 2 assessed study quality. Meta-analyses were conducted using a random-effects model using R software version 4.3.
Results
A total of 21 studies involving diverse populations and study designs were included. Observational studies suggested a moderate increase in risk for composite cardiovascular diseases (CVD), myocardial infarction (MI), and major adverse cardiac events (MACE) associated with PPI use, with pooled hazard ratios (HRs) of 1.20 (95% CI: 1.093–1.308) for CVD, 1.186 (95% CI: 1.069–1.303) for MI, and 1.155 (95% CI: 1.001–1.309) for MACE. However, RCTs showed no significant link between PPI therapy and negative cardiovascular events (Relative Risk: 1.016, 95% CI: 0.878–1.175). Substantial heterogeneity was observed among observational studies but not RCTs.
Conclusion
The findings indicate that while observational studies suggest a potential risk of adverse cardiovascular events with post-PCI use of PPI, RCTs do not support this association. Further large-scale, high-quality studies are required to understand the cardiovascular implications of individual PPIs better and optimize patient management post-PCI. This analysis shows the complexity of PPI use in patients with coronary artery diseases and the necessity to balance gastroprotective benefits against potential cardiovascular risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
- Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, Wardha, India.
- South Asia Infant Feeding Research Network (SAIFRN), Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, Wardha, India. zahirquazi@dmiher.edu.in.
- School of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.
- Graphic Era (Deemed to be University), Dehradun, Uttarakhand, India.
- Graphic Era Hill University, Clement Town, Dehradun, India.
Zitieren
APA
Padhi, B. K., Khatib, M. N., Zahiruddin, Q. S., Rustagi, S., Sharma, R. K., Sah, R., Satapathy, P., & Rao, A. P. (2024). Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-024-04029-0
Vancouver
Padhi BK, Khatib MN, Zahiruddin QS, Rustagi S, Sharma RK, Sah R, et al. Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2024. doi:10.1186/s12872-024-04029-0
BibTeX
@article{Padhi2024,
author = {Padhi, Bijaya K and Khatib, Mahalaqua Nazli and Zahiruddin, Quazi Syed and Rustagi, Sarvesh and Sharma, Rakesh Kumar and Sah, Ranjit and Satapathy, Prakasini and Rao, Arathi P},
title = {Adverse cardiovascular outcomes associated with proton pump inhibitor use after percutaneous coronary intervention: a systematic review and meta-analysis},
journal = {BMC Cardiovascular Disorders},
year = {2024},
doi = {10.1186/s12872-024-04029-0}
}
EUVIMED